ALB and Hyperkalemia: Combination therapy with SGLT2i and nsMRA not only achieved greater reduction in urine albumin creatinine ratio (uACR) compared to either monotherapy but also demonstrated a lower risk of hyperkalemia than monotherapy with nsMRA [57].